Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raludotatug deruxtecan with or without combination partners in relapsed high-grade serous ovarian, primary peritoneal, or fallopian tube cancer
2024-514674-47-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of raludotatug deruxtecan in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (9 cohorts), sponsored by Merck & Co. Primary endpoints: Number of participants who experience a dose-limiting toxicity, Number of participants with one or more adverse events and 2 more. Planned start Apr 2025; status: authorised.
02
Drugs
raludotatug deruxtecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2024-514674-47-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514674-47-00.